[A new group of competitive divalent Ca-antagonists (iproveratril, D 600, prenylamine) with potent inhibitory effects on electromechanical coupling in mammalian myocardium].
作者信息
Fleckenstein A, Tritthart H, Flackenstein B, Herbst A, Grün G
出版信息
Pflugers Arch. 1969;307(2):R25.
PMID:5814829
Abstract
摘要
相似文献
1
2
[Selective inhibition of myocardial contractility by competitive divalent Ca++ antagonists (iproveratril, D 600, prenylamine)].
Naunyn Schmiedebergs Arch Pharmakol. 1969;264(3):227-8.
3
4
5
[Separation of the divalent Ca++ antagonistic effect component from the beta-adrenolytic effects of cardio-depressive drugs on cultures of embryonic heart muscle cells].[从心脏抑制药物对胚胎心肌细胞培养物的β-肾上腺素能阻滞作用中分离二价钙离子拮抗效应成分]
Naunyn Schmiedebergs Arch Pharmakol. 1969;264(3):252-3.
6
[Limitation of the disappearance of energy-rich phosphate compounds in the hyperactive atrial and ventricular myocardium by divalent Ca-antagonistic inhibitors of electromechanical coupling (iprovdratril, D 600, prenylamine)].[通过电机械偶联的二价钙拮抗剂抑制剂（异博定、D 600、普尼拉明）限制高活性心房和心室心肌中富含能量的磷酸化合物的消失]
Pflugers Arch. 1969;312(1):R7-8.
7
8
[Electromechanical uncoupling on the uterine muscle by "musculotropic" relaxants].["肌向性"松弛剂对子宫肌的机电分离作用]
Naunyn Schmiedebergs Arch Pharmakol. 1969;264(3):239-40.
9
[Uterus relaxation by highly potent Ca plus,plus-antagonistic inhibitors of electro-mechanical coupling such as Isoptin (verapamil, iproveratril), compound D 600 and Segontin (prenylamine). Experiments on the isolated virgin rat uterus].[强效钙拮抗剂（如异搏定（维拉帕米，戊脉安）、化合物D 600和心可定（普尼拉明））对子宫电-机械耦联的抑制作用及子宫松弛作用。对未孕大鼠离体子宫的实验]
Klin Wochenschr. 1971 Jan;49(1):32-41. doi: 10.1007/BF01494064.
引用本文的文献
1
Vincristine combination with Ca channel blocker increase antitumor effects.长春新碱与钙通道阻滞剂联合使用可增强抗肿瘤效果。
Mol Biol Rep. 2019 Apr;46(2):2523-2528. doi: 10.1007/s11033-019-04706-w. Epub 2019 Mar 22.
2
Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.心得舒的撤市：首例与QT相关的死亡事件后的药理学、临床及监管结果展望
Ther Adv Drug Saf. 2018 Jun 18;9(8):475-493. doi: 10.1177/2042098618780854. eCollection 2018 Aug.
3
Discovery and Development of Calcium Channel Blockers.钙通道阻滞剂的发现与研发
Front Pharmacol. 2017 May 29;8:286. doi: 10.3389/fphar.2017.00286. eCollection 2017.
4
New generations of dihydropyridines for treatment of hypertension.用于治疗高血压的新一代二氢吡啶类药物。
J Geriatr Cardiol. 2017 Jan;14(1):67-72. doi: 10.11909/j.issn.1671-5411.2017.01.006.
5
Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis.钙通道阻滞剂在高血压和动脉粥样硬化中的抗氧化作用及治疗作用方式
Philos Trans R Soc Lond B Biol Sci. 2005 Dec 29;360(1464):2259-72. doi: 10.1098/rstb.2005.1774.
6
Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment.静脉注射和口服维拉帕米单次给药后及长期治疗期间，维拉帕米对P-R间期与维拉帕米血药浓度关系的影响。
Klin Wochenschr. 1980 Sep 15;58(18):919-25. doi: 10.1007/BF01477049.
7
Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.使用稳定同位素标记的维拉帕米同时测定 D,L-维拉帕米的静脉和口服药代动力学参数。
Eur J Clin Pharmacol. 1981 Jan;19(2):133-7. doi: 10.1007/BF00568400.
8
Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets.稳定同位素技术在评估经历广泛首过消除的药物生物利用度方面的优越性。维拉帕米片相对生物利用度的研究。
Eur J Clin Pharmacol. 1981 Jan;19(2):127-31. doi: 10.1007/BF00568399.
9
Clinical pharmacokinetics of verapamil in patients with atrial fibrillation.维拉帕米在心房颤动患者中的临床药代动力学
Eur J Clin Pharmacol. 1982;23(1):49-57. doi: 10.1007/BF01061377.
10
Studies on the calcium antagonistic action of tetrandrine: IX. Effects of tetrandrine on action potential and contraction of isolated guinea pig papillary muscles.汉防己甲素的钙拮抗作用研究：IX. 汉防己甲素对豚鼠离体乳头肌动作电位和收缩的影响。
Acta Acad Med Wuhan. 1984;4(3):133-7. doi: 10.1007/BF02856864.
Zotero 插件